Allergy Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), by Allergen Type (Food, Inhaled, Drug, Other Allergens), by Test Type (In vivo Test, In vitro Test), and by Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Allergy Diagnostics and Therapeutics Market was valued at USD 4.7 billion in 2023 and will surpass USD 9.2 billion by 2030; growing at a CAGR of 10.1% during 2024 - 2030.

The allergy diagnostics and therapeutics market is witnessing significant growth, driven by the rising prevalence of allergic conditions such as asthma, rhinitis, and food allergies worldwide. Factors such as changing lifestyles, urbanization, and increasing environmental pollution have contributed to the surge in allergic disorders, prompting the need for accurate diagnostics and effective treatment solutions. Advanced diagnostic tools, including immunoassays and molecular tests, have revolutionized allergy detection, enabling precise identification of allergens and tailored treatment plans for patients.

The market's expansion is further supported by innovations in therapeutic approaches, including biologics, sublingual immunotherapy (SLIT), and targeted medications designed to manage severe allergic reactions. Additionally, increasing awareness about allergies, along with government initiatives to improve healthcare infrastructure, has bolstered the adoption of advanced diagnostic and therapeutic solutions, ensuring robust market growth.

Diagnostics is the Largest Segment Owing to Rising Demand for Early Detection

The global Allergy Diagnostics and Therapeutics Market is expanding rapidly due to the increasing prevalence of allergic conditions, including food allergies, asthma, and seasonal rhinitis. This market is divided into two main categories: diagnostics and therapeutics, each comprising a variety of sub-segments. The rising awareness about allergies, coupled with technological advancements in diagnostic tools, has significantly driven the growth in this market. Diagnostic services are being increasingly prioritized, as early detection plays a critical role in managing allergic diseases and improving patient outcomes. This demand has been catalyzed by an increase in the number of allergy sufferers worldwide, coupled with improvements in diagnostic methodologies, leading to a higher market uptake.

Among the two key categories, the Diagnostics segment is the largest, primarily driven by innovations in allergy testing tools and equipment. Within diagnostics, Instruments form the largest sub-segment, accounting for a significant share of the overall market. The increasing adoption of advanced diagnostic instruments such as skin prick tests, intradermal tests, and specific IgE testing is contributing to this dominance. These instruments enable the accurate and efficient detection of allergens, which is essential for timely and effective allergy management. The increasing demand for allergy diagnostic instruments in hospitals, clinics, and diagnostic centers is further bolstering this sub-segment. With growing awareness about allergies and their treatments, the need for reliable diagnostic instruments will continue to drive this segment’s growth through 2030.

Food Allergens Are the Fastest Growing Sub-Segment Due to Rising Incidences of Food Allergies

Food allergies are becoming increasingly common worldwide, leading to rapid growth in the Food Allergens sub-segment of the Allergy Diagnostics and Therapeutics Market. This rise is driven by several factors, including changes in lifestyle, diet, and environmental factors. The increasing number of food allergy cases, especially in children, has created a greater demand for both diagnostics and therapeutics to address these conditions. Among food allergens, common triggers include peanuts, shellfish, dairy products, and tree nuts, which are well known for their potential to cause severe allergic reactions. This growing awareness of food allergies has prompted individuals to seek allergy testing and related treatments more frequently, driving the overall market.

The Peanut Allergy sub-segment is one of the fastest-growing areas within food allergens. Peanut allergies have seen a significant rise, particularly in Western countries, and this trend is fueling growth in both diagnostic and therapeutic sectors. Testing for peanut allergies is becoming increasingly common, as more people seek to avoid life-threatening reactions through early detection. As a result, the demand for advanced peanut allergy tests and therapies, including immunotherapy, is expected to rise substantially in the coming years. Moreover, the food allergen treatment landscape is evolving with novel therapies, including biologics and oral immunotherapy, offering promising solutions for peanut allergy sufferers. These innovations will drive substantial growth in the food allergen sub-segment of the market.

In Vivo Tests Lead Due to Their Popularity and Cost-Effectiveness

The Allergy Diagnostics and Therapeutics Market is also categorized by test type, including in vivo and in vitro tests. In vivo tests, which involve directly exposing the patient to allergens, are currently the leading sub-segment in this category. These tests are widely used in clinical settings due to their cost-effectiveness and high accuracy in identifying specific allergens. The most common in vivo tests include skin prick tests, intradermal tests, and patch tests. Among these, skin prick testing is the most popular method due to its simplicity, rapid results, and ability to test for multiple allergens simultaneously. As a result, in vivo testing continues to dominate the market, especially in regions with high healthcare accessibility.

The Skin Prick Test (SPT) is the largest and most commonly performed in vivo test, owing to its quick results and non-invasive nature. The test is typically used to diagnose allergies to food, pollen, dust mites, and insect stings. As one of the least expensive allergy tests, skin prick tests are preferred by healthcare providers, further contributing to the segment's growth. The rise in allergic diseases and the increasing use of skin prick testing for diagnosing a wide array of allergies are expected to drive the growth of this sub-segment. With advancements in precision medicine and the ability to test a broader range of allergens, the demand for skin prick testing is expected to remain strong in the years to come.

North America is the Largest Market Due to Strong Healthcare Infrastructure

In terms of regional dominance, North America leads the global Allergy Diagnostics and Therapeutics Market. This region, particularly the United States, is witnessing a surge in allergy-related conditions, driven by environmental changes, urbanization, and increased awareness. The high prevalence of allergic rhinitis, asthma, and food allergies in North America is prompting increased demand for both diagnostic services and therapeutic treatments. Furthermore, the region boasts advanced healthcare infrastructure, which facilitates the rapid adoption of new technologies and treatment modalities. The presence of leading diagnostic and pharmaceutical companies, along with strong reimbursement policies, also plays a critical role in expanding the market in North America.

In addition, North America benefits from high healthcare expenditure and government initiatives aimed at improving healthcare accessibility. The growing demand for personalized allergy treatments and precision diagnostics is also driving market growth in this region. Furthermore, major pharmaceutical and biotechnology companies in the U.S. are making significant strides in developing new allergy therapeutics, such as biologics and immunotherapy, positioning North America as the largest and most influential region in this market. As the market for allergy treatments continues to expand, North America is expected to maintain its leadership throughout the forecast period.

Leading Companies and Competitive Landscape

The Allergy Diagnostics and Therapeutics Market is highly competitive, with several global companies dominating the landscape. Major players in this market include Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, and ALK-Abelló. These companies are focusing on innovations in both diagnostics and therapeutics, with a particular emphasis on developing more precise and personalized treatments for allergic diseases. The increasing demand for allergy immunotherapy, along with the rising need for advanced diagnostic tools, has prompted these companies to invest heavily in research and development to expand their product offerings.

Additionally, strategic partnerships, mergers, and acquisitions are common in this market, as companies look to strengthen their market position and expand their reach. For example, AbbVie’s acquisition of Allergan has enabled the company to expand its allergy treatment portfolio, particularly in the immunotherapy space. In response to the growing need for allergy treatments, many companies are also looking to collaborate with academic institutions and research organizations to bring new therapies to market. Overall, the competitive landscape remains dynamic, with both established players and emerging companies continuously innovating to meet the evolving needs of the global allergy diagnostics and therapeutics market.

Recent Developments: -

• Thermo Fisher Scientific introduced advanced allergy testing kits, enhancing in vitro diagnostics for various allergens.
• AbbVie finalized its acquisition of Allergan, aiming to diversify its allergy treatment offerings, especially in immunotherapies.
• Novartis gained FDA approval for a new nasal spray targeting seasonal allergies, broadening its allergy therapeutics portfolio.
• GSK has expanded its partnership with leading research organizations to develop next-generation immunotherapies for allergic diseases.
• Regeneron announced promising results from its clinical trials for a new biologic treatment aimed at treating severe allergic asthma and rhinitis.

List of Leading Companies:

• R-Biopharm AG

Report Scope: